Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Norovirus Bivalent VLP Vaccine in Healthy Adults
NCT02142504Phase 2Completed
- Sponsor
- Takeda
- Start
- May 2014
- Primary completion
- Jan 2016
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NoV GI.1/GII.4 bivalent VLP vaccine in norovirus infection, sponsored by Takeda. Started May 2014; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT02142504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142504.